Cullinan Therapeutics (CGEM) EBITDA (2020 - 2026)

Cullinan Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$53.7 million for Q1 2026.

• In Q1 2026, EBITDA rose 2.36% year-over-year to -$53.7 million; the TTM figure through Mar 2026 stood at -$240.3 million (down 15.04% YoY), while the FY2025 annual figure was -$241.6 million, down 22.71% from the prior year.
• EBITDA for Q1 2026 stood at -$53.7 million, up from -$55.3 million in the prior quarter.
• The five-year high for EBITDA was $239.7 million in Q2 2022, with the low at -$75.8 million in Q2 2025.
• The 5-year median for EBITDA is -$48.9 million (2024), against an average of -$31.7 million.
• Peak annual rise in EBITDA reached 1543.5% in 2022, while the deepest fall reached 2480.25% in 2022.
• Cullinan Therapeutics' EBITDA stood at -$32.6 million in 2022, then tumbled by 39.49% to -$45.5 million in 2023, then retreated by 21.02% to -$55.0 million in 2024, then slipped by 0.38% to -$55.3 million in 2025, then grew by 2.83% to -$53.7 million in 2026.
• Business Quant data shows CGEM's EBITDA at -$53.7 million in Q1 2026, -$55.3 million in Q4 2025, and -$55.6 million in Q3 2025.